TESARO, Inc. (NASDAQ:TSRO) VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

TESARO, Inc. (NASDAQ TSRO) traded down 3.39% on Wednesday, reaching $129.77. 1,137,462 shares of the company’s stock traded hands. The company’s market cap is $7.03 billion. The firm’s 50 day moving average price is $123.46 and its 200 day moving average price is $143.36. TESARO, Inc. has a 12 month low of $86.52 and a 12 month high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.28) EPS. On average, equities analysts expect that TESARO, Inc. will post ($8.67) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/06/grant-c-bogle-sells-14167-shares-of-tesaro-inc-tsro-stock.html.

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in TESARO by 0.4% in the 1st quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after purchasing an additional 32,918 shares in the last quarter. BlackRock Inc. raised its position in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the last quarter. Vanguard Group Inc. raised its position in TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares during the last quarter. State Street Corp raised its position in TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after buying an additional 177,057 shares during the last quarter. Finally, BB Biotech AG raised its position in TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after buying an additional 53,408 shares during the last quarter.

Several research analysts recently issued reports on the stock. Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the stock a “buy” rating in a research note on Monday, June 5th. Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 target price on shares of TESARO and gave the stock a “buy” rating in a research note on Sunday, June 4th. Bank of America Corporation reissued a “buy” rating and set a $154.00 target price on shares of TESARO in a research note on Tuesday, June 20th. Finally, Gabelli assumed coverage on shares of TESARO in a research note on Friday, July 7th. They set a “buy” rating and a $175.00 target price on the stock. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $175.52.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.